MSA Glial Changes

Glial Changes in Multiple System Atrophy

The glial response in Multiple System Atrophy (MSA) plays a crucial role in disease progression. Unlike Parkinson's disease where neuronal alpha-synuclein pathology is primary, MSA features prominent glial alterations that contribute to both oligodendrocyte dysfunction and neuronal degeneration.

Overview

MSA exhibits multiple glial abnormalities:

• Oligodendrocytes: Primary pathological target with GCI formation
• Microglia: Chronic activation, inflammatory cytokine release
• Astrocytes: Reactive changes, support dysfunction

The multi-glial involvement distinguishes MSA from typical synucleinopathies.

Oligodendrocyte Pathology

Primary Oligodendrogliopathy

MSA is fundamentally an oligodendrogliopathy — a disease where oligodendrocytes are the primary target. This distinguishes MSA from other neurodegenerative disorders where neurons are primarily affected. The oligodendrocyte dysfunction precedes and drives the characteristic neuronal degeneration seen in MSA[@wenning2009].

See: [MSA oligodendrocyte pathology](/mechanisms/msa-oligodendrocyte-pathology)

Mechanisms of Oligodendrocyte Vulnerability

...

Glial Changes in Multiple System Atrophy

The glial response in Multiple System Atrophy (MSA) plays a crucial role in disease progression. Unlike Parkinson's disease where neuronal alpha-synuclein pathology is primary, MSA features prominent glial alterations that contribute to both oligodendrocyte dysfunction and neuronal degeneration.

Overview

MSA exhibits multiple glial abnormalities:

• Oligodendrocytes: Primary pathological target with GCI formation
• Microglia: Chronic activation, inflammatory cytokine release
• Astrocytes: Reactive changes, support dysfunction

The multi-glial involvement distinguishes MSA from typical synucleinopathies.

Oligodendrocyte Pathology

Primary Oligodendrogliopathy

MSA is fundamentally an oligodendrogliopathy — a disease where oligodendrocytes are the primary target. This distinguishes MSA from other neurodegenerative disorders where neurons are primarily affected. The oligodendrocyte dysfunction precedes and drives the characteristic neuronal degeneration seen in MSA[@wenning2009].

See: [MSA oligodendrocyte pathology](/mechanisms/msa-oligodendrocyte-pathology)

Mechanisms of Oligodendrocyte Vulnerability

| Factor | Mechanism | Evidence |
|--------|-----------|----------|
| High iron | Oxidative stress, Fenton chemistry | Post-mortem studies show iron accumulation in oligodendrocytes |
| Low antioxidant capacity | Limited glutathione | Susceptibility to oxidative stress |
| High metabolic demand | Myelin maintenance | High energy requirements |
| Slow turnover | Limited regeneration | Post-mitotic cells, minimal repair |

The combination of high iron content and limited antioxidant defenses makes oligodendrocytes particularly vulnerable to oxidative damage in MSA[@jellinger2014].

Glial Cytoplasmic Inclusions

The hallmark of MSA oligodendropathy is the glial cytoplasmic inclusion (GCI). These inclusions are composed primarily of aggregated alpha-synuclein filaments arranged in helical structures. GCIs are found in the cytoplasm of oligodendrocytes and contain:

• Alpha-synuclein filaments: Phosphorylated at Ser129
• Tubulin: Cytoskeletal components
• Ubiquitin: Protein degradation markers
• Heat shock proteins: Chaperone proteins

GCIs disrupt normal oligodendrocyte function by:

Impairing cytoplasmic transport

Altering protein synthesis

Disrupting membrane trafficking

Causing mitochondrial dysfunction

The density of GCIs correlates with disease severity and regional involvement, particularly in the striatonigral and olivopontocerebellar pathways[@papp1989].

Microglial Activation

Pattern of Activation

Microglia in MSA show a characteristic pattern of activation:

• Chronic activation throughout affected regions
• Progressive proliferation (microgliosis)
• Pro-inflammatory phenotype (M1-like)
• Sustained activation rather than transient response

This persistent microglial activation represents both a response to oligodendrocyte pathology and a driver of disease progression through sustained neuroinflammation[@stefanova2005].

Regional Distribution

Activated microglia concentrate in specific brain regions:

Striatonigral pathway — highest density, corresponding to parkinsonian features

Pontocerebellar white matter — associated with cerebellar ataxia

Autonomic nuclei — including the dorsal motor nucleus of the vagus

Cerebral cortex — less severe but present, particularly in prefrontal regions

The distribution of microglial activation mirrors the pattern of oligodendrocyte pathology and neuronal loss.

Inflammatory Mediators

MSA microglia release a range of pro-inflammatory cytokines and chemokines:

| Cytokine | Level | Effect |
|----------|-------|--------|
| IL-1β | ↑↑ | Pro-inflammatory, promotes neuronal death |
| TNF-α | ↑↑ | Neurotoxic, disrupts BBB |
| IL-6 | ↑ | Inflammatory, modulates astrocytes |
| TGF-β | Variable | Modulatory, context-dependent |

Additionally, microglial activation leads to:

• Reactive oxygen species (ROS) production
• Nitric oxide (NO) release
• Excitotoxin release (glutamate)
• Complement activation components

These mediators create a neurotoxic microenvironment that damages both oligodendrocytes and neurons[@bicker2013].

Impact on Disease Progression

Microglial activation contributes to disease progression through multiple mechanisms:

Neuronal dysfunction — inflammatory mediators directly damage neurons

Oligodendrocyte injury — cytokines promote GCI formation

Blood-brain barrier dysfunction — allows peripheral immune access

Alpha-synuclein spread — may facilitate prion-like propagation

Excitotoxicity — glutamate release contributes to excitotoxic damage

The bidirectional relationship between microglial activation and alpha-synuclein pathology suggests a vicious cycle where each process amplifies the other.

TSPO PET Imaging

Translocator protein (TSPO) PET imaging allows in vivo visualization of microglial activation in MSA:

• C-11 PK11195: First-generation TSPO ligand showing increased binding in MSA
• F-18 DPA-714: Second-generation ligand with improved signal

TSPO binding correlates with clinical severity and disease duration.

Astrocyte Changes

Reactive Astrocytosis

Astrocytes in MSA undergo significant morphological and biochemical changes:

• Glial fibrillary acidic protein (GFAP) upregulation — 3-5 fold increase in expression
• Morphological changes — hypertrophic processes, increased soma size
• S100B elevation — calcium-binding protein marker
• Variable inclusion formation — less prominent than in oligodendrocytes

Astrocytic changes are prominent in regions with significant oligodendrocyte pathology.

Dysfunctional Support

Astrocyte changes impair multiple normal astrocyte functions:

Metabolic support — reduced lactate delivery to neurons

Ion homeostasis — potassium buffering dysfunction

Neurotransmitter clearance — glutamate uptake reduced

Blood-brain barrier maintenance — endothelial support loss

Water homeostasis — AQP4 expression alterations

Comparison with Other Disorders

| Glial Response | MSA | PD | PSP |
|---------------|-----|-----|-----|
| Oligodendrocyte GCI | +++ | - | + |
| Microglial activation | ++ | ++ | ++ |
| Astrocytic plaques | - | - | + (PSP) |

MSA shows the most prominent oligodendrocyte involvement of any neurodegenerative disease.

Neuroinflammation Circuit

Multi-Glial Interaction

Phase 1 - Initiation

• Alpha-synuclein pathology in oligodendrocytes
• GCI formation
• Initial oligodendrocyte stress

Phase 2 - Propagation

• Microglial activation triggered by oligodendrocyte debris
• Astrocyte reactivity in response to inflammatory signals
• Cytokine and chemokine release

Phase 3 - Amplification

• Sustained neuroinflammation
• Neuronal dysfunction and loss
• Further oligodendrocyte injury
• Feed-forward loop establishment

Blood-Brain Barrier Involvement

Evidence for blood-brain barrier (BBB) disruption in MSA:

• Increased BBB permeability in putamen and substantia nigra
• Perivascular inflammation with pericyte dysfunction
• CSF protein elevation suggesting plasma protein leakage
• Post-mortem evidence of hemosiderin deposition

Therapeutic Implications

Anti-inflammatory Approaches

| Target | Agent | Status |
|--------|-------|--------|
| Microglial activation | Minocycline | No clear benefit |
| Cytokine inhibition | Anti-TNF | Preclinical |
| Glial modulation | Cannabis-derived | Investigational |

Challenges

• Blood-brain barrier limits drug delivery
• Microglial activation may have protective aspects
• Timing of intervention crucial

Emerging Therapeutic Strategies

Modulating microglial polarization

• TREM2 agonism to shift toward M2-like phenotype
• CSF1R antagonism to reduce microglial proliferation

Targeting astrocyte dysfunction

• AQP4 modulation
• Glutamate transporter enhancement

Biomarker Potential

Glial-Derived Markers

• CSF YKL-40 (chitinase-3-like protein): Elevated in MSA
• CSF IL-1β: Increased in active disease
• CSF GFAP: Elevated reflecting astrocyte reactivity

PET Imaging Biomarkers

• TSPO PET: Measures microglial activation in vivo
• Correlates with disease progression rate

Research Directions

Key Unanswered Questions

What triggers initial oligodendrocyte dysfunction in MSA?

How does alpha-synuclein pathology spread between glia and neurons?

Can neuroinflammation be effectively modulated without compromising protective functions?

What is the optimal timing for anti-inflammatory interventions?

Cross-Links

Related Mechanisms

• [MSA oligodendrocyte pathology](/mechanisms/msa-oligodendrocyte-pathology)
• [MSA neurotransmitter dysfunction](/mechanisms/msa-neurotransmitter-dysfunction)
• [Alpha-synuclein aggregation](/mechanisms/alpha-synuclein-aggregation)
• [Neuroinflammation pathway](/mechanisms/nlrp3-inflammasome-neurodegeneration)

Related Diseases

• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)

References

[Wenning GK et al., MSA as oligodendrogliopathy (2009)](https://pubmed.ncbi.nlm.nih.gov/19183779/)[@wenning2009]

[Stefanova N et al., Microglial pathology in MSA (2005)](https://pubmed.ncbi.nlm.nih.gov/15848385/)[@stefanova2005]

[Jellinger KA, Glial involvement in MSA (2014)](https://pubmed.ncbi.nlm.nih.gov/24852506/)[@jellinger2014]

[Bicker J et al., Neuroinflammation in MSA (2013)](https://pubmed.ncbi.nlm.nih.gov/23568583/)[@bicker2013]

[Papp MI et al., Glial inclusions in MSA (1989)](https://pubmed.ncbi.nlm.nih.gov/2676899/)[@papp1989]